Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envas versus EnaDenk for controlled primary hypertension
ACTRN12616001088437Phase 4Not yet recruiting
- Sponsor
- The University of Queensland
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of enalapril in hypertension (HTN), sponsored by The University of Queensland. Primary endpoint: Mean home systolic blood pressure difference. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
enalapril
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ACTRN12616001088437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001088437.